Jemperli (dostarlimab-gxly)

The analysis focuses on treatments that have demonstrated clinical benefit in advanced or recurrent disease, including pembrolizumab, dostarlimab, tisotumab vedotin, and mirvetuximab soravtansine. Their growing integration into clinical practice has reshaped therapeutic approaches, while ongoing research continues to refine optimal combinations, address resistance, and enhance biomarker-guided selection. Future developments are expected to unite immunologic, genomic, and computational strategies to achieve personalized and durable outcomes for patients with gynecologic malignancies.

Therapeutic progress in advanced endometrial cancer is mainly related to the first-line utilization of immunotherapy associated with chemotherapy, a strategy assessed in five randomized controlled trials, although at the moment, only dostarlimab is available in France...In second line, the combination of pembrolizumab and lenvatinib is the standard treatment if chemoimmunotherapy has not been used previously...The choice of the trial is guided by HER2 status in immunohistochemistry and results of new generation sequencing when available. The current trend towards the development of personalized medicine highlights the importance of pathological and molecular characterization of the tumor.

Treatment of LA HNSCC is multimodal and may include concomitant cisplatin-based chemoradiotherapy (CRT) or surgery; however, recurrence rates are high, and there is an unmet need for new treatments. The primary endpoint is event-free survival, with overall survival as a key secondary endpoint; safety and tolerability, pharmacokinetics, immunogenicity, biomarkers, and patient-reported outcomes will also be assessed. www.clinicaltrials.gov identifier is NCT06256588.

P1, N=21, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Mar 2026 --> Mar 2027

In this prognostic study of patients with advanced NSCLC receiving ICI treatment, the fully automated biomarker Serial CTRS predicted OS more effectively than resource-intensive RECIST and TVC measurements using the same scans.

The increased mutational burden in MMRd tumors enhances their susceptibility to immune checkpoint inhibitors such as pembrolizumab and dostarlimab, which have demonstrated considerable efficacy and altered the treatment approach for patients with advanced or recurrent MMRd EC. This review highlights the significance of MMR testing in risk stratification, prognosis, and planning of personalized treatment, ultimately improving patient outcomes.

P1/2, N=45, Active, not recruiting, iOnctura | Recruiting --> Active, not recruiting

P2, N=66, Active, not recruiting, Meghan Shea | Recruiting --> Active, not recruiting

P2, N=45, Recruiting, Chang Gung Memorial Hospital

P1, N=97, Active, not recruiting, GlaxoSmithKline | Trial completion date: Mar 2025 --> Mar 2026

P1, N=10, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2025 --> Feb 2029

The primary endpoint is event-free survival assessed by blinded independent central review. The key secondary endpoint is overall survival; additional secondary endpoints include pathological response assessed by residual viable tumor determined by local assessment, safety, and tolerability.Clinical trial registration: NCT05855200 (www.clinicaltrials.gov).